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There is an urgent need for biomarkers to identify malignant thyroid nodules from indeterminate follic-
ular lesions. We have used a subtractive proteomic strategy to identify novel biomarkers by selecting
ligands to goiter tissue from a 12-mer random peptide phage-displayed library using the BRASIL method
(Biopanning and Rapid Analysis of Selective Interactive Ligands). After three rounds of selection, two
highly reactive clones to the papillary thyroid tumor cell line NPA were further evaluated, and their spe-
ciﬁc binding to tumor proteins was conﬁrmed using phage-ELISA. The antibody-like peptide CaT12 was
tumor-speciﬁc, which was further tested by immunohistochemistry against TMAs (tissue microarrays)
comprised of 775 human benign and malignant tissues, including 232 thyroid nodular lesions: 15 normal
thyroid tissues, 53 nodular goiters (NG), 54 follicular adenomas (FA); 69 papillary thyroid carcinomas
(PTC); and 41 follicular carcinomas (FC). CaT12 was able to identify PTC among thyroid nodular lesions
with 91.2% sensitivity and 85.1% speciﬁcity, despite its non-speciﬁcity for thyroid tissues. Additionally,
the CaT12 peptide helped characterize follicular lesions distinguishing the follicular variant of PTC
(FVPTC) from FA with 91.9% accuracy; FVPTC from NG with 83.1% accuracy; FVPTC from the classic
PTC with 57.7% accuracy; and FVPTC from FC with 88.7% accuracy. In conclusion, our strategy to select
differentially expressed ligands to thyroid tissue was highly effective and resulted in a useful anti-
body-like biomarker that recognizes malignancy among thyroid nodules and may help distinguish follic-
ular patterned lesions.
 2013 Elsevier Ireland Ltd. Open access under the Elsevier OA license.1. Introduction
Thyroid cancer incidence rates have steadily increased over the
past few decades all over the world [1] and 56,460 new patients
are estimated to be diagnosed during 2012 in the USA [2]. The
accessible use of sensitive imaging detection methods is mainly
responsible for this increased incidence [3]. However, there are
evidences that other factors, including the exposure to environ-
mental carcinogenic factors, may have also contributed to this phe-
nomenon [3,4]. We have actually experienced real epidemics of
thyroid nodules referred to specialized diagnosis, and the cytolog-
ical exam of ﬁne-needle cell aspiration is the recommended meth-od by current guidelines to distinguish benign from malignant
lesions [5].
In most cases, the clinical features of the patients based on
ultrasonography and cytological ﬁndings enable appropriate case
management [5]. However, up to one third of the nodules submit-
ted to ﬁne needle aspiration biopsies may present an ‘‘indetermi-
nate’’ cytology, a pattern that remains burdened with inter-
observer variability and uncertainty regarding management [6].
Even the most experienced pathologists may have difﬁculties dis-
tinguishing cases of follicular variants of papillary thyroid carcino-
mas from simple benign hyperplasia, and many cases of follicular
adenomas are submitted to unnecessary surgeries because it is vir-
tually impossible to eliminate the risk of a follicular carcinoma in
cytological analyses [7]. A series of molecular markers for malig-
nancy have been proposed andmany of them appear to be effective
in reducing uncertainties [8,9]. However, clinical problems con-
cerning diagnosis of thyroid malignancies are not solved, and cer-
tainly are not appropriate to large populations.
In the present investigation, we have used a different approach
to distinguish thyroid malignancies. We employed phage display
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ious diseases [10–12], including many cancer types [13–24], and,
by using a direct selection (BRASIL) against goiter tissue, we were
able to obtain a highly reactive and discrimination marker for thy-
roid cancer diagnosis.
2. Materials and methods
Research Ethics Committees of three institutions approved this study: Federal
University of Uberlândia (UFU), State University of Campinas (UNICAMP) and Fun-
dação Antônio Prudente (Hospital AC Camargo, SP). All participants signed informed
consent forms.
2.1. Cell culture and patients’ samples
We have used the TPC-1 (Human thyroid papillary cancer) and NPA (Human
papillary cancer) cells, gently provided by Prof. J.M. Cerutti, from the Federal Uni-
versity of São Paulo. In addition, we have developed a primary human cell culture
using tissue obtained from a patient submitted to surgical removal of a multinodu-
lar goiter at the Surgery Center of UFU Hospital. Thyroid cancer cell lines and goiter-
derived cells were grown in RPMI 1640 medium supplemented with penicillin,
streptomycin, and 10% fetal bovine serum (Nutricell, Campinas-SP) and incubated
at 37 C in a humidiﬁed atmosphere containing 5% CO2.
Fresh tissues from patients with histologically-proved classic PTC and hyperpla-
sia were obtained from the Federal University of Uberlândia (UFU) Clinics’ Hospital,
and immediately frozen until use for protein binding testing.
The selected clone was tested by immunohistochemistry in formalin ﬁxed, par-
afﬁn embedded tissues from 775 patients reviewed for diagnostic conﬁrmation in
order to select the most representative areas designed to build tissue microarrays
(TMA, Beecher Instruments, Silver Springs, MD, USA). A ﬁrst TMA was composed
by 232 patient samples: 15 normal thyroid tissues, 53 nodular goiters, 54 follicular
adenomas, 69 papillary thyroid carcinomas (36 cases of the classical form and 33 of
the PTC follicular variant) and 41 follicular carcinomas. A second TMA was designed
to validate our results, and was constituted by 281 other cancer tissues (189 breast,
57 prostate and 35 kidney), 41 benign lesions (12 nevus atypical and 29 nevus) and
221 non-neoplastic tissues (including normal stomach, ovary, breast, prostate, kid-
ney, heart, muscle, brain, liver, lung and others).
Patients’ clinical information was obtained from their clinical records. Aggres-
siveness at diagnosis was ascertained using the Tumor Node Metastasis and stage
classiﬁcation systems for DTC as recommended by the American Thyroid Associa-
tion guidelines [5]. For statistical purpose we grouped patients classiﬁed as stage
II, III and IV in one class named ‘‘higher stages’’. Patients were followed with peri-
odic total body scans, serum TSH and thyroglobulin (Tg) measurements, according
to a standard protocol that included X-ray, ultrasonography, computed tomography
scan and other eventual procedures to detect distant metastasis for a period of 12–
298 months (43.50 ± 33.29 months). Patients presenting high non-stimulated ser-
um Tg levels (>2 mg/dl) were submitted to image evaluation. We deﬁned tumors
as persistent/recurrent and/or presenting long distance metastasis, according to
the aforementioned parameters.
2.2. Biopanning in cell surface
Biopanning was performed in three rounds using BRASIL method (Biopanning
and Rapid Analysis of Selective Interactive Interactive Ligands) [25] to verify phage
binding to intact cells.
2.3. DNA sequencing of selected phage clones
After three rounds, 96 blue colonies were randomly selected and their phage
single-strand DNA were isolated by the iodide buffer extraction procedure (Instruc-
tion Manual Ph.D.-12 Phage Display Peptide Library Kit) and analyzed with MegaB-
ace 1000 Genetic Analyzer (Amersham Biosciences) automatic capillary sequencer.
The nucleotide sequence of the gene III insert was sequenced with 96 gIII
sequencing primer 50-CCC TCA TAG TTA GCG TAA CG-30 by automated dye termina-
tor cycle sequencing. The amino acid sequence of the insert was deduced from the
nucleotide sequence using DNA2PRO software from RELIC program [26,27].
2.4. ELISA (enzyme-linked immunosorbent assay)
After extraction of papillary cancer and goiter proteins with extraction buffer
(Tris–HCl 20 mM pH7.2, EDTA 10 mM, EGTA 2 mM, sucrose 250 mM, DTT 1 mM,
Benzamidine 1 mM) proteins were diluted in sodium carbonate buffer (10 lg/ml
in 0.1 M NaHCO3) and immobilized into a 96-wells plate (Nunc Immuno Maxisorp,
Roche Diagnostics) by incubation it overnight at 4 C. That plate was subsequently
washed three times with PBST 0.1%, and blocked with BSA 3% (blocking buffer) for
three hours at 37 C. Plate wells were washed again three times, and each well was
incubated with 100 ll of phages supernatants for one hour at 37 C. After ﬁve
washes, recombinant phage particles were detected with peroxidase-conjugatedanti-M13 monoclonal antibody (Amersham Pharmacia Biotech Benelux, Roose-
ndaal, The Netherlands) using a 1:5000 dilution in blocking buffer. The peroxidase
staining reaction was developed in the presence of SIGMAFAST™ OPD (o-phenyl-
enediamine dihydrochloride) tablets (Sigma–Aldrich, São Paulo, SP, Brazil), and
then incubated at room temperature for 5 min, stopped with diluted acid solutions,
and the optical density (OD) values were measured on a microplate reader (TP-
READER – Thermo plate) at 492 nm.
2.5. Recombinant phage and synthetic peptide immunohistochemistry (IHC)
After deparafﬁnizing the tissues, the endogenous peroxidase was inactivated by
incubating the sections with 3% hydrogen peroxide for three times, 5 min each. The
tissue sections were then rinsed thoroughly in distilled water. For the biomarker
exposure, sodium citrate buffer (0.1 M) was heated to 95 C steamer, the slides were
submerged into the buffer for 35 min, washed for 5 min in running water, and
blocked with 3% skim milk (Molico Milk, Nestle, Brazil; 3% w/v in distilled water)
for 30 min at room temperature. Incubation with the primary marker (phage or syn-
thetic peptide) was then performed for 30 min at 37 C and overnight at 4 C. The re-
combinant phage CaT12, the synthetic peptide (Invitrogen, Carlsbad, CA, USA), and
the wild phage (no peptide) were diluted into 100 ll of the Novocastra Universal
IHC Blocking/Diluent 1000 (Leica Microsystems Inc, Buffalo Grove, IL, USA) contain-
ing 6  1011 pfu (viral particles/slide) or 1 lg synthetic peptide. As negative controls,
duplicate sections were incubated with 3% skimmilk proteins instead of speciﬁc pri-
mary antibodies. The sectionswerewashed four times in PBS for 5 min each followed
by one hour incubation with peroxidase-conjugated mouse anti-M13 secondary
antibody or streptavidin. After a washing step in PBS, peroxidase activity was visual-
ized by incubation in 3,30diaminobenzidine tetrahydrochloride (Liquid DAB, Sigma,
St. Louis, USA) for 5 min at room temperature. Sections were counterstained with
hematoxylin. Positive and negative controls were run in the same reaction batch.
Slides were independently scored by two experienced researchers (CFR and ECM),
both blinded to tumor features, and conﬁrmed by an experienced pathologist (JV).
2.6. Immunohistochemistry staining index
Signals were considered positive when reaction products were localized in the
expected cellular component. The staining index value was obtained by the sum of
intensity and distribution scores, and values of a staining index equal or greater
than 5 were considered positive.
The criteria employed for the intensity score were: 0, no staining; 1, weak; 2,
moderate; 3, strong. The criteria employed for the distribution score were: 0, no
staining; 1, staining of <25% of the cells; 2, between 25% and 50% of the cells; 3, be-
tween 50% and 75% of the cells; and 4, staining of >75% of the cells.
In addition, we employed the Automated Cellular Imaging System ACIS-III
(Chroma Vision Medical Systems, Inc, DAKO, San Juan Capistrano, CA, USA) for
IHC quantiﬁcation. Brieﬂy, each tissue spot was digitalized to the systems’ software,
and a computer algorithm, considering the intensity and extension of the brown
staining, attributed numerical values.
2.7. Streptavidin-bead precipitation assay
TPC-1 cells were lysed according to the instructions of the RIPA Buffer (Thermo
scientiﬁc, Rockford, IL, USA) kit; a protease inhibitor cocktail (1:100 dilution) (Sig-
ma–Aldrich, São Paulo, SP, Brazil) was added and the protein concentration was
determined using the BCA Protein Assay Kit (Thermo scientiﬁc). The synthetic pep-
tide (1 mg/ml) was N-terminal labeled with biotin, and mixed with 200 ll packed
Streptavidin-beads (Thermo scientiﬁc) for 1 h at 4 C, and incubated with 500 lg
of protein extracts for 4 h at room temperature. After washing four times with
TBS (Tris Buffered Saline), the proteins were eluted from the beads by addition
0.1 M glycine HCl buffer, pH 3.0, twice for 10 min each. The eluate was quantiﬁed
by the BCA Protein Assay Kit prior to proteins sequencing.
2.8. Protein sequencing by LC-MS/MS and target identiﬁcation
Eluted proteins were precipitated out of solution using the ProteoExtract kit
(Calbiochem) and the protein pellet was left to dry overnight in a sterile fumehood.
The lyophilized pellet was then resuspended in 50 mM ammonium bicarbonate (pH
8.0) and subjected to an in-solution tryptic digestion (Mike Myers, Cold Spring Har-
bor modiﬁed by Brett S. Phinney, UC Davis Proteomics Core, Davis, CA, USA). Di-
gested peptides were then de-salted using aspire tips (Thermo-Fisher Scientiﬁc,
RP30 tips) before being resuspended in loading buffer.
Digested peptides were analyzed using a LTQ-FT (Thermo Fisher Scientiﬁc) cou-
pled with a MG4 paradigm HPLC (Michrom, Auburn, CA, USA). The samples were
loaded onto a Michrom cap trap (0.5  2 mm) to be de-salted online. The peptides
were then separated using a Michrom Magic C18AQ (200 lm  150 mm) reversed-
phase column and eluted using a gradient for 60 min. Collision induced dissociation
was applied to the peptide samples and data was acquired with an isolation width
of 1, normalized collision energy of 35, and a resolution of 50,000. The spray voltage
on the Michrom captive spray was set to 1.8 kV with a heated transfer capillary
temperature of 200 C.
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ome Software, version 3.01). Samples were searched in Uniprot human sequences
databases, appended with the cRAP (commonly found laboratory contaminants)
and reverse decoy databases.
2.9. Statistical analysis
We employed GraphPrism 5.0 software to analyze the reactivity of the selected
phage and the synthetic peptide. ANOVA test with Bonferroni Post-hoc test, was
used to verify differences between means of OD value obtained by ELISA with phage
clones. Differences between benign and papillary cancer tissues for both biomarker
CaT12 phage and CaT12 peptide were tested with the Mann–Whitney U test (con-
tinuous variables and non-parametric analyses). Receiver operating characteristics
(ROC) curves were constructed to assess sensitivity, speciﬁcity, accuracy, and
respective areas under the curves (AUCs) with 95% conﬁdence interval (CI). For vi-
sual analysis and ACIS imaging, Fisher’s test was employed to determine the rela-
tionship between CaT12 phage or synthetic peptide for the different disease
groups in the TMA. We have used sensitivity and speciﬁcity parameters in the Fish-
er’s test to choose the cut-off value in the ROC curve analysis. Probability below
0.05 was considered signiﬁcant.
3. Results
3.1. Biopanning and speciﬁc enrichment of NPA-bound phages
The amount of phages obtained by in vitro biopanning was al-
ways higher than the output titers, indicating a successful enrich-
ment and speciﬁc binding to cancer cells.
3.2. Phage ELISA for clone detection
ELISA was performed on cancer and goiter cases in order to ana-
lyze the speciﬁc protein binding properties and to select the best
phage clones for immunohistochemistry testing. Clones CaT12
and CaT18 presented the highest absorbances for cancer proteins
(Fig. 1A) when compared to goiter proteins (P < 0.0001). A wild
phage used as control (M13) showed low reactivity. CaT12 and
CaT18 presented a consensus sequence showed on Fig. 1B.
3.3. Biomarker validation: phage and synthetic peptide
immunohistochemistry
To conﬁrm the ability of the selected clones to target cancer
cells, phage clone CaT12 and CaT18 were ampliﬁed, puriﬁed and
directly tested in IHC assays of the TMA built with cases of thyroid
cancer, adenoma, goiter and normal thyroid tissues. The M13 wildTest
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Fig. 1. Phage-ELISA and bioinformatics analyses of selected phage clones. (A) Phage-ELISA
reading at 492 nm and the X-axis shows the groups that were incubated with the differen
signiﬁcantly higher absorbance when compared to the control are indicated (=p < 0.00
CaT18. Green letters = hydroxyl + amine + basic amino acids; red = small + hydrophobic a
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CaT12 clone showed higher positivity than M13 wild phage in thy-
roid cancer cases, as demonstrated in Fig. 2. Furthermore, the
CaT12 synthetic peptide showed an increased signal (Fig. 2, A1),
which was not followed by CaT18 peptide that presented a mar-
ginal positivity (data not shown).
The cut-off values for CaT12 phage and CaT12 peptide were
chosen based on the ROC curve analyses (Fig. 2B2; Fig. 2B4, respec-
tively), which generated diagnostic parameters for the compari-
sons between cancer groups (Table 2). A signiﬁcant difference
(P < 0.0001) between cancer and benign diseases was found
(Fig. 2B1 and B3), which was superior for the CaT12 phage as a
biomarker.
We observed an overall higher positivity using CaT12 peptide in
goiters, FA and FC, whereas CaT12 phage was more frequently po-
sitive in CPTC and FCPTC, as demonstrated in Fig. 2. Visual and ACIS
analysis generated very comparable results as demonstrated in Ta-
ble 2 where we demonstrate the utility of the employed CaT12
phage and CaT12 peptide in the characterization of follicular pat-
terned lesions. Both visual and ACIS were valid analytical methods,
and presented similar values.
In fact, both CaT12 phage and synthetic peptide were able to
identify malignancy among follicular patterned lesions (goiter,
FA, FVPTC and PTC) and discriminate these lesions with consider-
able accuracy, as demonstrated in Table 3.
CaT12 was inversely correlated with patient’s age (Spearman
r = 0.2469, p = 0.0197) and was directly correlated with the
occurrence of metastasis (Spearman r = 0.3585, p = 0.0039) at fol-
low-up. We were not able to establish any other association be-
tween CaT12 and any clinical or tumor feature or with the
patients outcome.
We further employed CaT12 peptide in other tissues, as shown
in Fig. 3, demonstrating positivity in malignant tumors, and a weak
positivity in benign and normal tissues as presented in Fig. 3C and
Table 4.3.4. Immunohistochemistry validation
To validate CaT12 peptide we used different benign and malign
tissues as demonstrated in Fig. 3. We found a weak or negative
staining in benign lesions and in normal tissues, whereas tumors
were positive, as demonstrated in Table 4.ed phages
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Fig. 2. Immunohistochemistry with CaT12 phage and peptide in thyroid tissues. (A) Tissues of papillary thyroid cancer: (A1) CaT12 peptide; (A2) CaT12 phage; (A3) M13 wild
phage. Tissues of nodular goiter: (A4) CaT12 peptide; (A5) CaT12 phage; (A6) M13 wild phage. (400). (B) Comparison of ACIS values in benign and papillary cancer tissues.
(B1 and B3) Box-plot of CaT12 phage and peptide. (B2 and B4) represent ROC Curves of CaT12 phage and peptide, respectively.
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In order to further identify the target protein that could be bind-
ing to the CaT12 peptide, we have bound the biotinylated CaT12peptide to streptavidin-conjugated beads and thyroid cancer pro-
teins were magnetic captured. After magnetic separation, proteins
were eluted and sequenced by mass spectrometry (LC-MS/MS). A
list of proteins with the highest hits and number of matches is
Table 1
CaT12 recombinant phage and synthetic peptide positivity analyses considering visual and ACIS quantitative immunohistochemical scores for benign nodules (Nodular Goiter and
Follicular Adenomas) and differentiated thyroid cancer histological subtypes.
CaT12 Normal Goiter FA CPTC FVPTC FC
P/N Positivity (%) P/N Positivity (%) P/N Positivity (%) P/N Positivity (%) P/N Positivity (%) P/N Positivity (%)
Visual
Phage 0/15 0 9/53 16.98 9/54 16.67 36/36 100 26/32 81.25 7/41 20.00
Peptide 0/15 0 12/42 28.57 19/48 39.58 31/33 93.94 18/25 72.00 27/39 69.23
Acis
Phage 0/2 0 13/47 27.66 8/54 14.81 34/36 94.44 27/33 81.82 10/41 24.39
Peptide 0/15 0 12/44 27.27 21/47 44.68 32/35 91.43 22/30 73.33 28/40 70.00
Abbreviations: FA = follicular adenoma; CPTC = classic type PTC; FVPTC = follicular variant PTC; FC = follicular carcinoma; P = positive number of patients; N = total number of
patients. ACIS’s cut-off used for the peptide was >57.87, and for the phage was >45.68.
Table 2
Diagnostics’ parameters for the CaT12 phage and CaT12 peptide immunohistochemistry analyses taking into account the benign nodules (Nodular Goiter and Follicular
Adenomas) and differentiated thyroid cancer histological subtypes.
CaT12 Cut-off CPTC CPTC and FVPTC CPTC, FVPTC and FC
SEN (%) SPE (%) PPVa/NPVb or ACCc(%) SEN (%) SPE (%) PPVa/NPVb or ACCc (%) SEN (%) SPE (%) PPVa/NPVb or ACCc(%)
Visual
Phage – 100 85.12 66.67a 91.18 85.12 77.50a 64.22 85.12 79.55a
100b 94.50b 72.54b
Peptide – 93.94 70.48 50.00a 84.48 70.48 61.25a 78.35 70.48 71.03a
97.37b 89.16b 77.89b
Acis
Phage >45.68 94.44 79.61 94.17c 88.41 79.61 91.15c 55.00 79.61 72.50c
Peptide >57.87 91.43 68.87 83.53c 83.08 68.87 79.65c 78.10 68.87 76.23c
Abbreviations: NG = nodular goiter, FA = follicular adenoma, CPTC = classic type PTC; FVPTC = follicular variant PTC; FC = follicular carcinoma, SEN = sensibility,
SPE = speciﬁcity.
a PPV = positive predictive value.
b NPV = negative predictive value.
c ACC = accuracy. The cut-off employed in the Visual score was determined by Fisher’s exact test. The cut-off employed in the quantitative immunohistochemistry analysis
by ACIS was determined by the ROC curve analysis (see Methods description).
Table 3
Diagnostic value of CaT12 phage and CaT12 peptide for discriminating different
histopathological subtypes, according to ACIS immunohistochemical values.
Variable P* Sensibility (%) Speciﬁcity (%) Accuracy (%)
Phage
CPTC  FVPTC 0.2691 91.67 18.18 57.74
FVPTC  FA <0.0001* 81.82 85.19 91.92
FVPTC  FC <0.0001* 78.79 75.61 88.77
FC  FA 0.6253 24.39 85.19 52.94
FA  Goiter <0.0001* 85.19 27.66 76.36
FVPTC  Goiter <0.0001* 81.82 72.34 83.11
Peptide
CPTC  FVPTC 0.0199* 91.43 26.67 66.86
FVPTC  FA 0.0254* 76.67 55.32 65.18
FVPTC  FC 0.8680 73.33 30.00 51.17
FC  FA 0.0512* 70.00 55.32 62.18
FA  Goiter 0.0583 46.68 72.73 61.53
FVPTC  Goiter <0.0001* 73.33 70.45 78.48
Abbreviations: FA = follicular adenoma; CPTC = classic type PTC; FVPTC = follicular
variant PTC; FC = follicular carcinoma.
* P < 0.05.
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speciﬁc ligand.
4. Discussion
Identiﬁcation of malignant thyroid nodules from indeterminate
follicular lesions is difﬁcult and biomarkers can barely distinguish
follicular variants of papillary thyroid carcinomas from simple be-
nign hyperplasia. We have used a subtractive phage display selec-
tion against goiter tissue aiming the improvement of thyroid
cancer diagnosis. We have chosen this technology due to itssuccessful applications in biomarkers’ discovery, especially when
short random peptides are selected against speciﬁc target mole-
cules, such as those with antitumor activity [20] or for drug deliv-
ery [28].
A highly reactive peptide, CaT12, although not speciﬁc for thy-
roid tissues, was able to identify malignancy among thyroid nodu-
lar lesions and characterize follicular patterned lesions. In fact, its
accuracy to identify follicular patterned lesions is comparable to
most of the currently used immunohistochemical markers em-
ployed in differential diagnosis of indeterminate nodules [29,30].
Moreover, this peptide is associated to features of DTC aggressive-
ness, such as age and the occurrence of metastasis, suggesting a
potential clinical use.
We observed different results concerning the CaT12 recombi-
nant clone and its synthetic peptide, with increased staining and
positivity for the phage clone in cancer samples. This fact may be
due to the speciﬁc epitope conformation generated by the fusion
of the peptide with the N-terminal region of the bacteriophage pIII
protein. On the other hand, higher reactivity of the peptide was ob-
served in controls (goiter and adenomas), probably because of the
lower afﬁnity of the peptide alone, without the conformational
rearrangement of the peptide-pIII fusion. Therefore, there is a po-
tential contribution of phage-coat proteins for the peptide afﬁnity
as discussed elsewhere [31,32].
CaT12 strongly stained both the membrane and the cytoplasm
of papillary thyroid cancer cells. Since normal thyroid cells do
not stain, its protein target may be produced during physiological
cellular growth. Benign thyroid lesions, such as follicular adeno-
mas and hyperplasia, presented a very weak staining, reinforcing
the hypothesis that we are dealing with a protein involved in cel-
lular growth. We have identiﬁed several protein targets of the
Fig. 3. Immunohistochemistry with CaT12 peptide in different tissues. Cancer tissues: Positive: (A1) kidney; (A2) prostate; (A3) breast. Negative: (B1) kidney; (B2) prostate;
(B3) breast. Non-neoplastic tissues: Positive: (C1) bladder; (C2) respiratory epithelium; (C3) small intestine. Negative: (D1) parathyroid; (D2) nevus; (D3) muscle.
C.F. Reis et al. / Cancer Letters 335 (2013) 306–313 311CaT12 ligand, mostly cytokeratins, which are currently being
tested.
In fact, serum cytokeratin fragments have been found in thyroid
nodule patients [33] and have even been associated with the risk of
metastases [34]. Interestingly, cytokeratin-19 immunohistochem-
istry is largely employed in the differential diagnosis of follicular
patterned lesions [29], although it was not recognized in our mass
spectrometry analysis. However, due to the smaller speciﬁcity andbinding afﬁnity of the synthetic peptide in comparison to the re-
combinant phage, it is possible that the peptide may partially bind
to a conserved cytokeratin domain, which may explain the align-
ment (hits) of digested protein fragments with many cytokeratin
sequences. On the other hand, the higher speciﬁcity found for the
CaT12 recombinant phage suggests that its fused peptide sequence
may be partially complemented by the amino terminal sequence of
the pIII phage capsid protein improving its binding afﬁnity.
Table 4
Immunohistochemistry positivity of the CaT12 peptide in different tissues.
Histopathological diagnosis Visual analysis
N Positive cases (%)
Non-malignant
Nevus atypical 12 0
Nevus communes 29 3.45
Nonneoplastic tissues* 206 15.53
Normal breast 5 0
Normal prostate 5 0
Normal kidney 5 60
Total 262 13.74
Malignant
Breast cancer 189 53.96
Prostate cancer 57 70.18
Kidney cancer 35 74.29
Total 281 59.79
* Different human nonneoplastic tissues including pancreas, liver, lung, breast,
prostate and brain.
Table 5
Identiﬁcation of putative protein targets of the Cat12 peptide ligand by LC-MS/MS.
Protein name Acession number MW (KDa)
Keratin, type II cytoskeletal 1 P04264 66
Keratin, type I cytoskeletal 9 P35527 62
Keratin, type I cytoskeletal 10 P13645 59
Keratin, type I cytoskeletal 14 P02533 52
Keratin, type II cytoskeletal 2 P35908 65
Hornerin Q86YZ3 282
Keratin, type II cytoskeletal 6A P02538 60
Keratin, type II cytoskeletal 5 P13647 62
312 C.F. Reis et al. / Cancer Letters 335 (2013) 306–313In conclusion, we have designed a novel approach to select spe-
ciﬁc peptide ligands to thyroid cancer cells, which allowed us to
identify a highly reactive antibody-like peptide that maybe readily
used in the cellular diagnosis of thyroid nodules, discriminating
indeterminate benign follicular lesions from carcinomas with high
accuracy. This speciﬁc ligand may also be a potential therapeutic
agent or drug carrier for future treatment strategies of thyroid
cancer.
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